Temple Faculty Physicians is experiencing technical issues with phone lines. If you are experiencing an emergency, please visit your nearest emergency room. If you would like to schedule an appointment with your provider or have general questions or requests, please contact us by using myTempleHealth.

myTempleHealth
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Dr. Joseph D’Orazio Provides Perspective to the New York Times on the Challenges That Will Still Exist Following the Designation of Xylazine as an ‘Emerging Drug Threat’

View All News

Joseph D’Orazio, MD, Associate Professor of Clinical Emergency Medicine at the Lewis Katz School of Medicine at Temple University, provided perspective to the New York Times for an article describing the challenges that will still exist following the designation of xylazine as an “emerging drug threat” by the White House’s Office of National Drug Control Policy. Xylazine, also known as tranq or tranq dope, is an animal sedative that has been increasingly found in fentanyl and heroin and causes fast-moving necrotic wounds and heavy sedation.